Eslovènia - eslovè - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

welding gmbh & co. kg - eplerenon - filmsko obložena tableta - eplerenon 25 mg / 1 tableta - eplerenon

Eslovènia - eslovè - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

welding gmbh & co. kg - eplerenon - filmsko obložena tableta - eplerenon 50 mg / 1 tableta - eplerenon

Eslovènia - eslovè - Ecolab

ecolab deutschland gmbh -

Unió Europea - eslovè - EMA (European Medicines Agency)

bayer animal health gmbh - iron(iii) ion, toltrazuril - toltrazuril, kombinacije - prašiči (pujski) - za sočasnem preprečevanju kliničnih znakov coccidiosis (kot so driska) v novorojenčku pujski na kmetijah, s potrjeno zgodovino coccidiosis zaradi cystoisospora suis, in preprečevanje pomanjkanja železa anemija.

Unió Europea - eslovè - EMA (European Medicines Agency)

baxter holding b.v. - insulin human (rdna) - sladkorna bolezen - zdravila, ki se uporabljajo pri diabetesu - inpremzia is indicated for the treatment of diabetes mellitus.

Unió Europea - eslovè - EMA (European Medicines Agency)

nps pharma holdings limited - obščitnični hormon (rdna) - osteoporoza, postmenopavz - kalcij homeostaza - zdravljenje osteoporoze pri ženskah po menopavzi z visokim tveganjem za zlome (glejte poglavje 5). dokazano je bilo znatno zmanjšanje pojavnosti vretenčnih, toda ne zlomov kolka.

Unió Europea - eslovè - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doksorubicinijev klorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastična sredstva - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Unió Europea - eslovè - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - mogamulizumab - sezary syndrome; mycosis fungoides - antineoplastična sredstva - poteligeo je indiciran za zdravljenje odraslih bolnikov z mycosis fungoides (mf) ali sézary sindrom (ss), ki so prejeli vsaj eno predhodno sistemsko terapijo.

Unió Europea - eslovè - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - fentanil - pain; cancer - analgetiki - pecfent je indiciran za zdravljenje prebijajoče bolečine pri odraslih, ki že prejemajo vzdrževalno opioidno terapijo za kronično bolečino pri raku. prebojna bolečina je prehodno poslabšanje bolečine, ki se pojavi na ozadju kontinuirane bolečine, ki jo sicer nadzira. bolniki, ki prejemajo preživnino opioidne terapije so tisti, ki so pri čemer se vsaj 60 mg oralno morfin dnevno, vsaj 25 micrograms od transdermalni fentanil na uro, vsaj 30 mg oxycodone dnevno, vsaj 8 mg oralno hydromorphone dnevno ali equi-analgetik odmerek drugo opioidov za teden dni ali več.

Unió Europea - eslovè - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - zdravila za zdravljenje bolezni kosti - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.